Iniciar Sesión Regístrate abrir menu

Bibliografía Científica

Artículos por temáticas

En este apartado encontrará una actualización mensual de Enfermedad de Alzheimer y Demencias

8059 ARTÍCULOS , VIENDO DEL 2701 AL 2715

Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein

Parums DV.

Med Sci Monit. 2021 Jul 26;27:e934077. doi: 10.12659/MSM.934077.

Aducanumab: First Approval

Dhillon S.

Drugs. 2021 Aug;81(12):1437-1443. doi: 10.1007/s40265-021-01569-z.

Improvement of cognitive performance by a nutraceutical formulation: Underlying mechanisms revealed by laboratory studies

Shea TB.

Free Radic Biol Med. 2021 Oct;174:281-304. doi: 10.1016/j.freeradbiomed.2021.07.039. Epub 2021 Aug 2.

Brain Glucose Transporters: Role in Pathogenesis and Potential Targets for the Treatment of Alzheimer's Disease

Szablewski L.

Int J Mol Sci. 2021 Jul 29;22(15):8142. doi: 10.3390/ijms22158142.

Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease

Kile S, Au W, Parise C, Rose K, Donnel T, Hankins A, Au Y, Chan M, Ghassemi A.

BMC Neurosci. 2021 Aug 6;22(1):49. doi: 10.1186/s12868-021-00651-2.

Dietary and supplemental long-chain omega-3 fatty acids as moderators of cognitive impairment and Alzheimer's disease

Wood AHR, Chappell HF, Zulyniak MA.

Eur J Nutr. 2022 Mar;61(2):589-604. doi: 10.1007/s00394-021-02655-4. Epub 2021 Aug 15.

Effects of Noninvasive Brain Stimulation (NIBS) on Cognitive Impairment in Mild Cognitive Impairment and Alzheimer Disease: A Meta-analysis

Wang T, Guo Z, Du Y, Xiong M, Yang Z, Ren L, He L, Jiang Y, McClure MA, Mu Q.

Alzheimer Dis Assoc Disord. 2021 Jul-Sep 01;35(3):278-288. doi: 10.1097/WAD.0000000000000464.

Leukotriene receptor antagonist use and cognitive decline in normal cognition, mild cognitive impairment, and Alzheimer's dementia

Xiong LY, Ouk M, Wu CY, Rabin JS, Lanctôt KL, Herrmann N, Black SE, Edwards JD, Swardfager W.

Alzheimers Res Ther. 2021 Sep 3;13(1):147. doi: 10.1186/s13195-021-00892-7.

Novel insights into RIPK1 as a promising target for future Alzheimer's disease treatment

Li S, Qu L, Wang X, Kong L.

Pharmacol Ther. 2022 Mar;231:107979. doi: 10.1016/j.pharmthera.2021.107979. Epub 2021 Sep 2.

A meta-analysis of randomised controlled trials of physical activity in people with Alzheimer's disease and mild cognitive impairment with a comparison to donepezil

Pisani S, Mueller C, Huntley J, Aarsland D, Kempton MJ.

Int J Geriatr Psychiatry. 2021 Oct;36(10):1471-1487. doi: 10.1002/gps.5581. Epub 2021 May 25.

Is resveratrol a prospective therapeutic strategy in the co-association of glucose metabolism disorders and neurodegenerative diseases?

Ribeiro R, Santos AC, Calazans MO, De Oliveira ACP, Vieira LB.

Nutr Neurosci. 2022 Nov;25(11):2442-2457. doi: 10.1080/1028415X.2021.1972514. Epub 2021 Sep 11.

The role of orexin in Alzheimer disease: From sleep-wake disturbance to therapeutic target

Gao F, Liu T, Tuo M, Chi S.

Neurosci Lett. 2021 Nov 20;765:136247. doi: 10.1016/j.neulet.2021.136247. Epub 2021 Sep 14.

Multi-mechanical waves against Alzheimer's disease pathology: a systematic review

Monteiro F, Sotiropoulos I, Carvalho Ó, Sousa N, Silva FS.

Transl Neurodegener. 2021 Sep 24;10(1):36. doi: 10.1186/s40035-021-00256-z.

Effects of Supplementation with Folic Acid and Its Combinations with Other Nutrients on Cognitive Impairment and Alzheimer's Disease: A Narrative Review

Puga AM, Ruperto M, Samaniego-Vaesken ML, Montero-Bravo A, Partearroyo T, Varela-Moreiras G.

Nutrients. 2021 Aug 26;13(9):2966. doi: 10.3390/nu13092966.

Editorial: How Will Aducanumab Approval Impact AD Research?

Weiner MW, Aisen PS, Beckett LA, Green RC, Jagust W, Morris JC, Okonkwo O, Perrin RJ, Petersen RC, Rivera Mindt M, Saykin AJ, Shaw LM, Toga AW, Trojanowski JQ.

J Prev Alzheimers Dis. 2021;8(4):391-392. doi: 10.14283/jpad.2021.46.

Actualización mensual Regístrese para recibir los avisos de actualización

Si quiere recomendar un artículo/publicación para completar este apartado puede hacerlo a través del formulario de contacto para su valoración.

En ningún caso la información facilitada constituye asesoramiento por parte de Zambon

Con el aval de:

Logo SEN Logo WIS

En colaboración con:

Zambon Neurociencias